Basic Information
| LncRNA/CircRNA Name | FOXD2-AS1 |
| Synonyms | NA |
| Region | GRCh38_1:47432133-47434641 |
| Ensemble | ENSG00000237424 |
| Refseq | NR_026878 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | autophagy | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | thyroid cancer |
| ICD-0-3 | C73.9 |
| Methods | qRT-PCR , Western blot , RIP etc. |
| Sample | thyroid cancer tissues and the adjacent normal tissues ,normal primary thyroid follicular epithelial cells (PTFE) and thyroid duct cell carcinoma cells TT ,Thyroid cancer cell lines(PTC cell lines (B-CPAP and BHT101),anaplastic thyroid cancer (ATC) cell lines (CAL-62 and 8305C)) |
| Expression Pattern | up-regulated |
| Function Description | FOXD2-AS1 was upregulated in thyroid carcinoma tissues and cells. High expression of FOXD2-AS1 significantly correlated with clinical stage, recurrence of thyroid carcinoma.Silencing FOXD2-AS1 inhibited cancer stem cell-like phenotypes and attenuates the anoikis resistance in vitro.Downregulating FOXD2-AS1 represses the tumorigenesis of thyroid carcinoma cells in vivo.FOXD2-AS1 acts as a competitive endogenous RNA (ceRNA) for miR-7-5p, up-regulating the expression of telomerase reverse transcriptase (TERT), which further promotes the cancer stem cells features and anoikis resistance in thyroid cancer cells. |
| Pubmed ID | 31024447 |
| Year | 2019 |
| Title | LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer |
External Links
| Links for FOXD2-AS1 | GenBank HGNC NONCODE |
| Links for thyroid cancer | OMIM COSMIC |